Evidence map›Paper›PMID 30826861›Full record

Trial reportSurgery today2019

Phase II trial of induction chemotherapy with carboplatin and paclitaxel plus bevacizumab in patients with stage IIIA to IV nonsquamous non-small cell lung cancer.

Kazuhiro Imai, Taku Nakagawa, Ikuo Matsuzaki, Kimito Orino, Hajime Saito, Kazuhiro Sato, Masaaki Sano, Katsutoshi Nakayama, Yusuke Sato, Satoru Motoyama and 3 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Surgery today, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Kazuhiro ImaiDepartment of Thoracic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan. i-karo@mui.biglobe.ne.jp.ORCID http://orcid.org/0000-0003-4490-7862
Taku NakagawaOmagari Kosei Medical Center, Daisen, Japan.
Ikuo MatsuzakiNoshiro Yamamoto Medical Association Hospital, Noshiro, Japan.
Kimito OrinoYuri General Hospital, Yurihonjo, Japan.
Hajime SaitoDepartment of Thoracic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan.
Kazuhiro SatoDepartment of Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
Masaaki SanoDepartment of Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
Katsutoshi NakayamaDepartment of Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
Yusuke SatoDepartment of Thoracic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan.
Satoru MotoyamaDepartment of Thoracic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan.
Kyoko NomuraDepartment of Public Health, Akita University Graduate School of Medicine, Akita, Japan.
Hiroyuki ShibataDepartment of Clinical Oncology, Akita University Graduate School of Medicine, Akita, Japan.
Yoshihiro MinamiyaDepartment of Thoracic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, 010-8543, Akita, Japan.
Akita University · JPSangi (Japan) · JPYamamoto Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSurgery remains the best curative treatment option for non-small cell lung cancer (NSCLC), but is of benefit only to patients with localized disease. A meta-analysis showed a significant beneficial effect of induction chemotherapy on survival, but there is still no clear evidence. This phase II study was conducted to establish whether induction chemotherapy with carboplatin (CBDCA) and paclitaxel (PTX) plus bevacizumab prior to surgery reduces the risk of progression.

methodsThe subjects of this study were 29 patients with treatment-naive nonsquamous NSCLC (clinical stages IIIA to IV). Patients received PTX (200 mg/m

resultsThe overall response rate was 72.4%. Of the 29 patients, ten underwent surgery after the induction chemotherapy and complete resection was achieved in 7 (70%). The median progression-free-survival (PFS) time and the 3-year PFS rate were 0.92 years and 16.2%, respectively. The median overall survival (OS) time and the 3-year OS rate were 1.96 years and 44.9%, respectively.

conclusionCombined modality therapy with surgery after induction chemotherapy with CBDCA and PTX plus bevacizumab is clinically feasible and tolerable for patients with unknown or negative molecular profiles.

Indexed as

Induction ChemotherapyAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingPaclitaxelSurvival RateTreatment OutcomeBevacizumabCarboplatinPaclitaxelBevacizumabCarboplatinInduction chemotherapyLung cancerPaclitaxel

Identifiers

PMID30826861
OpenAlexW2920269315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.